Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine
Cleveland Clinic · University of Auckland · +3 more institutions
Indexed incrossrefpubmed
Abstract
Background
Inflammatory bowel disease (IBD) is commonly treated with immunomodulators such as azathioprine and 6-mercaptopurine (6-MP). Studies examining lymphoma risk in IBD patients treated with these medications have been underpowered and have yielded conflicting conclusions.
Aims
The purpose of this meta-analysis was to provide a more precise estimate of the relative risk of lymphoma among IBD patients treated with azathioprine or 6-MP.
Citation impact
800
total citations
- FWCI
- 50.98
- Percentile
- 100%
- References
- 27
Citations per year
Authors
5- AKAhmed Kandiel
Cleveland Clinic, University of Auckland, Lenox Hill Hospital, University of Pennsylvania
- AGA G Fraser
University of Auckland
- BIB I Korelitz
Lenox Hill Hospital
- CBC Brensinger
University of Pennsylvania
- JDJ D LewisCorresponding
Huntsworth Health (United States)
Topics & keywords
Keywords
- Azathioprine
- Relative risk
- Medicine
- Mercaptopurine
- Internal medicine
- Inflammatory bowel disease
- Lymphoma
- Gastroenterology
No related works found for this paper.